305 related articles for article (PubMed ID: 24398046)
1. Tumorgrafts as in vivo surrogates for women with ovarian cancer.
Weroha SJ; Becker MA; Enderica-Gonzalez S; Harrington SC; Oberg AL; Maurer MJ; Perkins SE; AlHilli M; Butler KA; McKinstry S; Fink S; Jenkins RB; Hou X; Kalli KR; Goodman KM; Sarkaria JN; Karlan BY; Kumar A; Kaufmann SH; Hartmann LC; Haluska P
Clin Cancer Res; 2014 Mar; 20(5):1288-97. PubMed ID: 24398046
[TBL] [Abstract][Full Text] [Related]
2. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.
Monsma DJ; Monks NR; Cherba DM; Dylewski D; Eugster E; Jahn H; Srikanth S; Scott SB; Richardson PJ; Everts RE; Ishkin A; Nikolsky Y; Resau JH; Sigler R; Nickoloff BJ; Webb CP
J Transl Med; 2012 Jun; 10():125. PubMed ID: 22709571
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
4. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.
Thong AE; Zhao H; Ingels A; Valta MP; Nolley R; Santos J; Young SR; Peehl DM
Urol Oncol; 2014 Jan; 32(1):43.e23-30. PubMed ID: 23911681
[TBL] [Abstract][Full Text] [Related]
5. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
Becker MA; Haluska P; Bale LK; Oxvig C; Conover CA
Mol Cancer Ther; 2015 Apr; 14(4):973-81. PubMed ID: 25695953
[TBL] [Abstract][Full Text] [Related]
8. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
9. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
[TBL] [Abstract][Full Text] [Related]
11. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
12. WAP four-disulfide core domain protein 2 promotes metastasis of human ovarian cancer by regulation of metastasis-associated genes.
Chen Y; Huang L; Wang S; Liu T; Wu Y; Li JL; Li M
J Ovarian Res; 2017 Jul; 10(1):40. PubMed ID: 28679402
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Colon-Otero G; Weroha SJ; Foster NR; Haluska P; Hou X; Wahner-Hendrickson AE; Jatoi A; Block MS; Dinh TA; Robertson MW; Copland JA
Gynecol Oncol; 2017 Jul; 146(1):64-68. PubMed ID: 28461031
[TBL] [Abstract][Full Text] [Related]
14. A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX).
Cheng Y; Qin SK; Li J; Dai GH; Shen BY; Ying JE; Ba Y; Liang H; Wang XB; Xu Y; Zhou L; Ding KF; Qin YR; Yang SJ; Guan WX; Zheng H; Wang Q; Song H; Zhu YP
J Cancer Res Clin Oncol; 2022 Mar; 148(3):673-684. PubMed ID: 33864522
[TBL] [Abstract][Full Text] [Related]
15. Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.
Scalici JM; Thomas S; Harrer C; Raines TA; Curran J; Atkins KA; Conaway MR; Duska L; Kelly KA; Slack-Davis JK
J Nucl Med; 2013 Nov; 54(11):1883-9. PubMed ID: 24029657
[TBL] [Abstract][Full Text] [Related]
16. Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
Stuckey A; Fischer A; Miller DH; Hillenmeyer S; Kim KK; Ritz A; Singh RK; Raphael BJ; Brard L; Brodsky AS
BMC Cancer; 2011 Jul; 11():308. PubMed ID: 21781307
[TBL] [Abstract][Full Text] [Related]
17. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
[TBL] [Abstract][Full Text] [Related]
19. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.
Bhattacharyya S; Saha S; Giri K; Lanza IR; Nair KS; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Basal E; Weaver AL; Visscher DW; Cliby W; Sood AK; Bhattacharya R; Mukherjee P
PLoS One; 2013; 8(11):e79167. PubMed ID: 24236104
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.
Butler KA; Hou X; Becker MA; Zanfagnin V; Enderica-Gonzalez S; Visscher D; Kalli KR; Tienchaianada P; Haluska P; Weroha SJ
Neoplasia; 2017 Aug; 19(8):628-636. PubMed ID: 28658648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
